Literature DB >> 356577

Reduced quinidine clearance in elderly persons.

H R Ochs, D J Greenblatt, E Woo, T W Smith.   

Abstract

The influence of age on quinidine pharmacokinetics was assessed in 22 healthy male and female volunteers; 14 of the subjects were young (aged 23 to 34 years) and 8 elderly (aged 60 to 69 years). All subjects received 180 to 300 mg of quinidine base by constant rate intravenous infusion over 10 to 15 minutes. The concentration of total and unbound quinidine in multiple serum samples and in urine collected within 48 hours after the administration of quinidine qas determined with spectrophotofluorometric assay. Mean kinetic values for total quinidine in the young subjects were: elimination half-life (t 1/2 beta), 7.3 hours; total volume of distribution (Vd), 2.39 liters/kg; total clearance, 4.04 ml/min per kg; renal clearance 1.43 ml/min per kg; and percent unbound, 24.6 In the elderly subjects, the values for Vd (2.18 liters/kg) and percent unbound (28.2) did not differ significantly from these values in the young subjects. However, in the elderly subjects t 1/2 beta was significantly longer (9.7 hours, P less than 0.05) and total quinidine clearance significantly less (2.64 ml/min per kg, P less than 0.005) than in the young subjects. Renal clearance of quinidine in the elderly was also significantly less (0.99 ml/min per kg, P less than 0.05) than in the young and was associated with lower rates of creatinine clearance in the elderly (r = 0.66). Reduced clearance of quinidine and prolongation of its elimination half-life could predispose to toxicity in the elderly unless the dose were appropriately adjusted.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 356577     DOI: 10.1016/0002-9149(78)90944-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  19 in total

Review 1.  Age-related changes in protein binding of drugs: implications for therapy.

Authors:  M K Grandison; F D Boudinot
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 2.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 3.  Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations.

Authors:  Arduino A Mangoni
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 4.  Is antiarrhythmic treatment in the elderly different? a review of the specific changes.

Authors:  Vera H M Deneer; Norbert M van Hemel
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

5.  Pharmacokinetics of quinidine in male patients. A population analysis.

Authors:  C N Verme; T M Ludden; W A Clementi; S C Harris
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

6.  Population pharmacokinetics of quinidine.

Authors:  K Fattinger; S Vozeh; H R Ha; M Borner; F Follath
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 7.  Plasma protein binding of drugs in the elderly.

Authors:  S M Wallace; R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

Review 8.  Adverse effects of antiarrhythmic drugs.

Authors:  J B Schwartz; D Keefe; D C Harrison
Journal:  Drugs       Date:  1981-01       Impact factor: 9.546

Review 9.  Drug dosage in the elderly. Is it rational?

Authors:  K Turnheim
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 3.923

Review 10.  Clinical pharmacokinetics of quinidine.

Authors:  H R Ochs; D J Greenblatt; E Woo
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.